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The iron chelator desfer~oxamine has been applied in many studies of ~thoio~~i states by several investi~tors. The 
resulting decreases in cellular and tissue damage have been interpreted as an indication of the involvement of iron-media- 
ted radical species. Although the nature and location of the iron species have not been identified, the assumption has 
often been made that desferrioxamine is able to enter cells. This paper reports investigations of the ability of desferriox- 
amine to cross the erythrocyte membrane in comparison with that of specific hydroxypyridone iron chelators by assessing 
their interaction with haemoglobin. 
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1. INTRODUCTION 
Desferrioxamine is currently the only iron 
chelator in therapeutic use for the treatment of 
pathological disorders involving iron excess and 
iron decompartmentalisation. However, this 
chelator is not entirely non-toxic at standard or 
high doses [l-5] during prolonged clinical use 
unless the dosage regimen is closely adjusted to the 
iron status of the patient. In particular, cerebral 
and ocular toxicity have been reported in some pa- 
tients (reviewed in [6]). 
In vitro studies have proposed that the iron- 
binding site of desferrioxamine has an oxidising ef- 
fect when in direct interaction with haemoglobin 
released from erythrocytes (7,8]; this may relate to 
the ability of the drug to interact with the superox- 
ide radical [P-11] resulting in the formation of 
methaemoglobin. Other studies have demonstrated 
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the ability of desferrioxamine to act as an electron 
donor [12,13]. Its ability to suppress the propaga- 
tion of membrane lipid peroxidation 113-151 and 
to act as a peroxyl radical scavenger 1161 has also 
been reported. 
This paper reports investigations of the ability of 
desferrioxamine to cross the membrane of the 
erythrocyte in comparison with that of specific 
hydrox~~idone iron chelators selected on the 
basis of their varying capacities for traversing cell 
membranes [ 171. The responses were assessed of (i) 
haemoglobin within the erythrocyte to the iron 
chelators presented extracellularly, in the presence 
and absence of iron-mediated oxidative stress, and 
of (ii) haemoglobin, released from erythrocytes, 
and directly exposed to the drugs. The results sug- 
gest that desferrioxamine does not enter the 
erythrocyte within a timescale longer than its half- 
life in plasma. 
2. EXPERIMENTAL 
Fresh human erythrocytes were obtained from normal, 
healthy donors and used immediately. After centrifugation, the 
plasma and buffy coat were removed and the erythrocytes 
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washed three times with iso-osmotic phosphate buffer, pH 7.4. 
Erythrocytes at a 5% suspension in iso-osmotic buffer were in- 
cubated at 37°C for various time intervals up to 24 h. For 
haemolysis the original erythrocytes were lysed in 20 vols of ice- 
cold hypo-osmotic buffer, pH 7.4, the membranes removed and 
treated as in the intact cell experiments. Experiments employing 
a range of proportions of volumes of the hypo-osmotic 
haemolysis buffer, down to 2 vols, were performed such that 
the final haemoglobin to chelator ratio was as close as possible 
to that which would be attainable assuming total uptake by the 
erythrocytes of the desferrioxamine. 
The specific model of iron-mediated oxidative stress con- 
sisted of a iron(Il)/ascorbate/hydrogen peroxide stress system 
[18,19] presented extracellularly to erythrocytes at levels such as 
to induce intracellular iron stress in the form of iron-containing 
inclusion bodies from denatured haemoglobin, akin to the 
situation in thalassaemia major [20]. The experimental systems 
consisted of iron(I1) sulphate (lOOaM), ascorbic acid (I mM), 
hydrogen peroxide (200rM). Iron chelators were utilised at 
concentrations such that desferrioxamine was in an appropriate 
ratio to haemoglobin as that observed in situations of 
microbleeding and in a 4-fold excess of the exogenously added 
iron (400 pM), giving the same ratio as that in the clinical treat- 
ment of iron overload. Iron chelators were added prior to the 
iron stress in all cases. Specific hydroxypyridone iron chelators, 
which coordinate iron in a 3 : 1 ratio (structures in fig. l), were 
selected on the basis of their relative abilities to traverse cell 
membranes [17]: CP02 crosses the membrane (Kparr 0.5 for oc- 
tanol/Tris buffer 20 mM), CP22 will enter the membrane readi- 
1~ (&art 1.35), whereas CP47 does not enter the membrane 
(&an <0.002). Final concentrations of the hydroxypyridone 
chelators (1 mM) were estimated on the basis of their 
stoichiometry of binding of iron compared to the equimolar 
stoichiometry of desferrioxamine. 
Erythrocyte filterability was assessed by filtering suspensions 
(30 x lo6 cells/ml) through 3 pm Nucleopore membranes. 
Erythrocyte transit time (Torr) was then calculated by analysis 
of complete flow profiles from zero to 1 min [21]. 
Methaemoglobin formation was measured by the decrease in 
absorbance at 620 nm after the addition of cyanide [22]. 
Pyridin-4-one Pyridin-2-one 
Fig. 1. The structures of hydroxy pyridin-2-one and hydroxy 
pyridin-4-one compounds. 3-Hydroxy pyridin-4-one, RI = 
-CH,; RZ = CHZCH~CH~, CP22; Rz = -(CH&CH- 
coo+, CP47. 3-Hydroxy pyridin-2-one, Rz = -CH2CHj, 
I CPO2. 
NH,+ 
3. RESULTS AND DISCUSSION 
The effects of desferrioxamine and ferrioxamine 
on the filterability of erythrocytes under iron- 
mediated oxidative stress are shown in table 1. 
Filterability is expressed in terms of transit time. 
Exposure of normal erythrocytes extracellularly to 
the iron stress system for 4 h revealed a 2.5fold in- 
crease in the transit time of the cells (table 1). 
When desferrioxamine was incorporated into the 
incubation, prior to the iron stress system, to sup- 
press the generation of oxygen radicals ex- 
tracellularly by chelating the iron, the diminished 
filterability (increased transit time) was not 
modified. Control incubations of erythrocytes 
with ferrioxamine or desferrioxamine in the 
presence of peroxide and ascorbate show that 
although ferrioxamine does not alter the filterabili- 
ty, desferrioxamine does increase the pore transit 
time by more than 30% after 4 h, which cannot be 
accounted for by the effects of ascorbate and 
hydrogen peroxide on the erythrocytes. This result 
may imply a weak interaction of desferrioxamine 
at the membrane surface. 
The effectiveness of the hydroxypyridone com- 
pounds in the inhibition of intracellular 
haemoglobin oxidation induced by the ex- 
tracellular iron-mediated oxidant stress system in 
comparison with desferrioxamine, is shown in 
table 2. CP22, CP47 and desferrioxamine were the 
Table 1 
The effects of desferrioxamine and ferrioxamine on the 
filterability of erythrocytes under iron-mediated oxidative stress 
Additions Transit time 
(Torr) 
None 0.67 * 0.18 
(14) 
Iron/ascorbate/hydrogen peroxide 1.67 & 0.38 
(IO) 
Desferrioxamine + iron stress 1.37 + 0.47 
(6) 
Ferrioxamine + iron stress 1.81 + 0.44 
(4) 
Desferrioxamine + ascorbate/hydrogen 1.02 * 0.18 
peroxide (4) 
Ferrioxamine + ascorbate/hydrogen 0.63 + 0.16 
peroxide (4) 
Filterability is expressed in terms of transit time. Cell 
suspensions contained 30 x lo6 cells/ml 
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Table 2 
The effects of hydroxypyridones and desferrioxamine on 
intracellular haemoglobin oxidation induced by extracellular 
iron-mediated oxidative stress 
Additions % methaemoglobin 
5h 24 h 
None 2 +1 16 + 1 
Iron stress 11 +4 85*7 
Desferrioxamine (0.4 mM) + iron stress 2 f 1 40 + 5 
CP02 (1 mM) + iron stress 30 f 5 68 + 7 
CP22 (1 mM) + iron stress 4.8 + 3 40 + 4 
CP47 (1 mM) + iron stress 3.1+2 38+5 
n=4 
most effective in suppressing iron-induced 
methaemoglobin production, at 5 h of incubation, 
compared to the extent of haemoglobin oxidation 
in their absence, whereas CP02 responded dif- 
ferently, enhancing haemoglobin oxidation. After 
prolonged incubation for 24 h, CP22, CP47 and 
desferrioxamine decreased the intracellular 
haemoglobin oxidation induced by extracellular 
exposure to the iron stress system to approximately 
the same extent. CP02 was again less effective. 
In order to clarify the effects of the chelators in 
the absence of the iron stress system, control 
erythrocytes were treated with the iron chelators 
alone and the response assessed in terms of 
methaemoglobin production (table 3). None of the 
erythrocyte incubations showed any variation in 
response from that of the control in the absence of 
the chelators except for CP02 which enhanced the 
oxidation of haemoglobin. This chelator is the one 
of the selected hydroxypyridones which crosses the 
membrane readily and the enhanced 
methaemoglobin production can be explained by 
the direct interaction with haemoglobin on enter- 
ing the cell. 
To determine the reactivity of the compounds 
with haemoglobin their direct exposure to red cell 
haemolysates was investigated. Table 3 also in- 
dicates that the response of haemoglobin in 
membrane-free haemolysates to direct interaction 
with the drugs in terms of the extent of 
haemoglobin oxidation is much enhanced in the 
presence of CP02 and desferrioxamine but this 
toxic response is not elicited by CP22 and CP47. 
The relative abilities of the iron chelators to in- 
duce haemoglobin oxidation and the responses 
observed when the compounds are presented to the 
intact cells or directly to the haemolysate suggest 
that desferrioxamine does not cross the erythrocyte 
membrane under these conditions and does not 
enter the erythrocytes within a timescale longer 
than its half-life in plasma. Desferrioxamine has a 
low lipid solubility, K,,, 0.01 [17], and it is possi- 
ble that it is this characteristic of the drug which 
limits its ability to penetrate most cells of the body 
[61. 
The iron chelator desferrioxamine has been ap- 
plied by several investigators in studies in vitro of 
pathological states in which excess superoxide 
generation has been implicated; a resulting 
decrease in tissue damage has led to the conclusion 
Table 3 
The effects of the hydroxypyridones and desferrioxamine. on haemoglobin by 
direct and by extracellular exposure 
Additions % methaemoglobin 
Erythrocytes Haemolysate 
5h 24 h 5h 10 h 24 h 
None 0 16k 1 2.6 + 1 5.7 2 * 14 zk 3 
Desferrioxamine 
0.4 mM 0 16 + 1 14.2 + 3 28.0 t 5 53.5 8 k 
0.1 mM 0 16 + 1 10.0 k 2 13.0 + 2 30.0 * 1 
CP02 (1 mM) 2.0 f 1 25 + 5 4.2 i 2 35 i8 
CP22 (1 mM) 0 14 f 3 3.oi 1 6.0 2 k 11.5 + 2 
CP47 (1 mM) 0 14 zk 2 3.0* 1 5.5+1 11.7*3 
n=4 n=fi 
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that hydroxyl radicals or other reactive species in- 
volving iron-oxygen complexes may have been in- 
volved. Although the nature and location of the 
iron species have not been identified in many in- 
stances, the assumption has often been made that 
desferrioxamine is able to enter the cells in ques- 
tion, for which the evidence is very limited. For ex- 
ample, the ability of desferrioxamine to clear iron 
from iron-loaded hepatocytes may be mediated by 
a mechanism of uptake specific to hepatocytes 
[23]. The iron from these cells would eventually be 
excreted in the bile, while the source of iron ex- 
creted in the urine may all be extracellular chela- 
tion, a mechanism which would include iron 
release from reticuloendothelial cells [24]. 
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